karmma-2 cohort 2b update: ide-cel for transplant-ineligible patients with high-risk myeloma
Published 4 weeks ago • 113 plays • Length 5:23Download video MP4
Download video MP3
Similar videos
-
2:16
updates from the karmma-3 trial: safety profile of ide-cel in tce r/r multiple myeloma
-
4:04
ide-cel versus standard regimens in tce r/r multiple myeloma: updated analysis of karmma-3
-
1:53
karmma-4: ide-cel for newly diagnosed high-risk multiple myeloma
-
5:16
updated karmma results: ide-cel in r/r myeloma
-
1:58
karmma study shows improved qol in patients with r/r multiple myeloma treated with ide-cel
-
4:04
the future of myeloma treatment and the possibility of cure
-
6:23
how long will i live with multiple myeloma and is there a cure?
-
5:14
multiple myeloma part 2
-
5:15
promising clinical trials for multiple myeloma: karmma, cartitude and evolve
-
1:13
longitudinal findings from the karmma trial: improved qol in patients treated with ide-cel
-
1:21
an update on cartitude-2: cilta-cel in patients with multiple myeloma in second line
-
2:06
subanalysis of the karmma trial: predicting complete response to car-t in multiple myeloma
-
2:01
an update on cohort c from the cartitude-2 trial
-
3:54
karmma-3: pros in patients with tce r/r myeloma treated with ide-cel vs standard regimens
-
6:55
karmma2: efficacy and safety of idecabtagene vicleucel in hrmm pts with early relapse after asct
-
2:37
tandem meetings myeloma highlights: pano/gembumel with autosct, karmma-3 & more
-
2:40
lba: karmma-3 results - ide-cel vs standard regimens in triple-class exposed multiple myeloma
-
1:40
karmma-3: phase iii trial of idecabtagene vicleucel in r/r myeloma
-
1:55
recent updates on celmods in multiple myeloma
-
1:59
the growing importance of celmods in the treatment of r/r multiple myeloma
-
2:44
myeloma qol through induction and maintenance
-
1:55
impact of age on ide-cel efficacy in the karmma trial